Congenital platelet disorders: Overview of their mechanisms, diagnostic evaluation and treatment

Haemophilia

Volumn 12, Issue SUPPL. 3, 2006, Pages 128-136

  Hayward, Catherine P M ^a   Rao, A K ^b   Cattaneo, M ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Inherited bleeding disorders; Inherited platelet isorders; Platelet aggregation; Platelet function; Platelet secretion

Indexed keywords

AMINOCAPROIC ACID; AMINOCAPROIC ACID DERIVATIVE; DESMOPRESSIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PROCOAGULANT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; TRANEXAMIC ACID; TRANSCRIPTION FACTOR; VON WILLEBRAND FACTOR;

AGE; AUTOSOMAL DOMINANT INHERITANCE; BERNARD SOULIER DISEASE; BLEEDING; BLOOD CELL COUNT; BLOOD CLOTTING; CYTOGENETICS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG INDUCED HEADACHE; DRUG INFUSION; FAMILIAL DISEASE; FAMILY HISTORY; FLUID RETENTION; FLUSHING; GENETIC HETEROGENEITY; GLANZMANN DISEASE; HEMATURIA; HUMAN; HYPOTENSION; IMMUNOPRECIPITATION; IN VIVO STUDY; INTRAUTERINE CONTRACEPTIVE DEVICE; LABORATORY TEST; MAXIMUM TOLERATED DOSE; MENORRHAGIA; MENSTRUATION DISORDER; ORTHOPEDIC SURGERY; PREVALENCE; PRIORITY JOURNAL; QUEBEC THROMBOCYTE DISORDER; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SEX DIFFERENCE; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN BRUISING; STRUCTURE ANALYSIS; SYMPTOM; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE ANOMALY; THROMBOCYTE DISORDER; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; THROMBOCYTE STRUCTURE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION; VON WILLEBRAND DISEASE; WESTERN BLOTTING; X CHROMOSOME LINKAGE; X CHROMOSOME LINKED DISORDER;

BLOOD PLATELET DISORDERS; BLOOD PLATELETS; HUMANS; PLATELET ADHESIVENESS; PLATELET AGGREGATION;

EID: 33646129692     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01270.x     Document Type: Review

References (60)

1. Michelson AD. How platelets work: Platelet function and dysfunction. J Thromb Thrombolysis 2003; 16: 7-12.
2. Ruggeri ZM. von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003; 1: 1335-42.
3. Savage B, Cattaneo M, Ruggeri ZM. Mechanisms of platelet aggregation. Curr Opin Hematol 2001; 8: 270-6.
4. Ni H, Freedman J. Platelets in hemostasis and thrombosis: Role of integrins and their ligands. Transfus Apher Sci 2003; 28: 257-64.
5. Rao AK, Jalagadugula G, Sun L. Inherited defects in platelet signaling mechanisms. Semin Thromb Hemost 2004; 30: 525-35.
6. Rao AK. Congenital disorders of platelet secretion and signal transduction. In: Colman RW, Hirsch J, Marder VJ, Clowes A, George JN, eds. Haemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: J.B. Lippincott, 2001: 890-904.
7. Nurden AT. Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost 2005; 3: 1773-82.
8. Cattaneo M. Inherited platelet abnormalities. Thromb Res 2005; 115(Suppl. 1): 10-3.
9. Drachman JG. Inherited thrombocytopenia: When a low platelet count does not mean ITP. Blood 2004; 103: 390-8.
10. Geddis AE, Kaushansky K. Inherited thrombocytopenias: Toward a molecular understanding of disorders of platelet production. Curr Opin Pediatr 2004; 16: 15-22.
11. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003; 1: 1628-36.
12. Hayward CPM. Inherited platelet disorders. Curr Opin Hematol 2003; 10: 362-8.
13. Nurden AT, Nurden P. Inherited defects of platelet function. Rev Clin Exp Hematol 2001; 5: 314-34.
14. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: The spectrum of clinical disease. Blood 1990; 75: 1383-95.
15. Balduini CL. Giant platelet syndromes and the MYH9 mutations. Lab Hematol 2004; 10: 187-8.
16. Balduini CL, Savoia A. Inherited thrombocytopenias: Molecular mechanisms. Semin Thromb Hemost 2004; 30: 513-23.
17. Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998; 91: 4397-418.
18. Cattaneo M. The P2 receptors and congenital platelet function defects. Semin Thromb Hemost 2005; 31: 168-73.
19. Clemetson KJ. Platelet glycoproteins and their role in diseases. Transfus Clin Biol 2001; 8: 155-62.
20. George JN, Nurden AT. Inherited disorders of the platelet membrane: Glazmann thrombasthenia, Bernard-Soulier syndrome, and other disorders. In: Colman RW, Hirsch J, Marder VJ, Clowes A, George JN, eds. Haemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia: J.B. Lippincott, 2001: 921-43.
21. Nurden AT, Phillips DR, George JN. Platelet membrane glycoproteins: historical perspectives. J Thromb Haemost 2006; 4: 3-9.
22. Hayward CPM. Diagnosis and management of mild bleeding disorders. Hematology (Am Soc Hematol Educ Program) 2005; 423-8.
23. Quiroga T, Goycoolea M, Munoz B et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: Comparative study in 148 patients. J Thromb Haemost 2004; 2: 892-8.
24. Weiss HJ. Scott syndrome: A disorder of platelet coagulant activity. Semin Hematol 1994; 31: 312-9.
25. Lee CA. Women and inherited bleeding disorders: Menstrual issues. Semin Hematol 1999; 36 (Suppl. 4): 21-7.
26. Philipp CS, Dilley A, Miller CH et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003; 1: 477-84.
27. Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312-9.
28. Rao AK, Koike K, Willis J et al. Platelet secretion defect associated with impaired liberation of arachidonic acid and normal myosin light chain phosphorylation. Blood 1984; 64: 914-21.
29. Gabbeta J, Yang X, Kowalska MA, Sun L, Dhanasekaran N, Rao AK. Platelet signal transduction defect with Galpha subunit dysfunction and diminished Galphaq in a patient with abnormal platelet responses. Proc Natl Acad Sci USA 1997; 94: 8750-5.
30. Patel YM, Patel K, Rahman S et al. Evidence for a role for Galphai1 in mediating weak agonist-induced platelet aggregation in human platelets: reduced Galphai1 expression and defective Gi signaling in the platelets of a patient with a chronic bleeding disorder. Blood 2003; 101: 4828-35.
31. Yang X, Sun L, Ghosh S, Rao AK. Human platelet signaling defect characterized by impaired production of inositol-1,4,5-triphosphate and phosphatidic acid and diminished pleckstrin phosphorylation: Evidence for defective phospholipase C activation. Blood 1996; 88: 1676-83.
32. Gabbeta J, Yang X, Sun L, McLane MA, Niewiarowski S, Rao AK. Abnormal inside-out signal transduction-dependent activation of glycoprotein IIb-IIIa in a patient with impaired pleckstrin phosphorylation. Blood 1996; 87: 1368-76.
33. Sun L, Mao G, Rao AK. Association of CBFA2 mutation with decreased platelet PKC-theta and impaired receptor-mediated activation of GPIIb-IIIa and pleckstrin phosphorylation: Proteins regulated by CBFA2 play a role in GPIIb-IIIa activation. Blood 2004; 103: 948-54.
34. Hayward CPM. Inherited disorders of platelet alpha-granules. Platelets 1997; 8: 197-209.
35. Kahr WH, Zheng S, Sheth PM et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001; 98: 257-65.
36. McKay H, Derome F, Haq MA et al. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 2004; 104: 159-65.
37. Gunay-Aygun M, Huizing M, Gahl WA. Molecular defects that affect platelet dense granules. Semin Thromb Hemost 2004; 30: 537-47.
38. Lo B, Li L, Gissen P et al. Requirement of VPS33B, a member of the Sec1/ Munc18 protein family, in megakaryocyte and platelet alpha-granule biogenesis. Blood 2005; 106: 4159-66.
39. Jin Y, Mazza C, Christie JR et al. Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): Hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood 2004; 104: 4010-9.
40. White JG, de Alarcon PA. Platelet spherocytosis: A new bleeding disorder. Am J Hematol 2002; 70: 158-66.
41. Solum NO. Procoagulant expression in platelets and defects leading to clinical disorders. Arterioscler Thromb Vasc Biol 1999; 19: 2841-6.
42. Weiss HJ, Lages B, Zheng S, Hayward CPM. Platelet factor V New York: A defect in factor V distinct from that in factor V Quebec resulting in impaired prothrombinase generation. Am J Hematol 2001; 66: 130-9.
43. Sramek A, Eikenboom JC, Briet E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Intern Med 1995; 155: 1409-15.
44. Moffat KA, Ledford-Kraemer MR, Nichols WL, Hayward CPM. Variability in clinical laboratory practice in testing for disorders of platelet function: Results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb Haemost 2005; 93: 549-53.
45. Linden MD, Frelinger AL III, Barnard MR, Przyklenk K, Furman MI, Michelson AD. Application of flow cytometry to platelet disorders. Semin Thromb Hemost 2004; 30: 501-11.
46. Peerschke EI. The laboratory evaluation of platelet dysfunction. Clin Lab Med 2002; 22: 405-20.
47. Rand ML, Leung R, Packham MA. Platelet function assays. Transfus Apher Sci 2003; 28: 307-17.
48. White JG. Use of the electron microscope for diagnosis of platelet disorders. Semin Thromb Hemost 1998; 24: 163-8.
49. Drouin A, Favier R, Masse JM et al. Newly recognized cellular abnormalities in the gray platelet syndrome. Blood 2001; 98: 1382-91.
50. Smith MP, Cramer EM, Savidge GF. Megakaryocytes and platelets in alpha-granule disorders. Baillieres Clin Haematol 1997; 10: 125-48.
51. Cattaneo M. Desmopressin in the treatment of patients with defects of platelet function. Haematologica 2002; 87: 1122-4.
52. Kaleelrahman M, Minford A, Parapia LA. Use of recombinant factor VIIa in inherited platelet disorders. Br J Haematol 2004; 125: 95-6.
53. Ozelo MC, Svirin P, Larina L. Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome. Ann Hematol 2005; 84: 816-22.
54. Poon MC, d'Oiron R. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International registry on recombinant factor VIIa and congenital platelet disorders group. Blood Coagul Fibrinolysis 2000; 11 (Suppl. 1): S55-68.
55. Rao AK, Ghosh S, Sun L et al. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial. Thromb Haemost 1995; 74: 1071-8.
56. Cattaneo M, Mannucci PM. Desmopressin. In: Michelson AD, ed. Platelets. San Diego: Academic Press, 2002: 855-66.
57. Lethagen S. Desmopressin in the treatment of women's bleeding disorders. Haemophilia 1999; 5: 233-7.
58. Siegel JE, Kouides PA. Menorrhagia from a haematologist's point of view. Part II: Management. Haemophilia 2002; 8: 339-47.
59. Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. Br J Obstet Gynaecol 2004; 111: 1425-8.
60. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia 2002; 8: 787-93.